Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
Sponsor: Usynova Pharmaceuticals Ltd.
Summary
A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeks
Official title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2025-10-21
Completion Date
2026-05-30
Last Updated
2025-11-18
Healthy Volunteers
No
Interventions
Tyk2 inhibitor
Specific dose of Tyk2 inhibitor on specific days
Placebo
Specified dose of Placebo on specified days.
Locations (1)
Shanghai Skin Disease Hospital
Shanghai, China